Humanization of fibroblast growth factor 1 single‐chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells

He, Xiaomin; Du, Shuyuan; Gao, Shiqian; Chen, Jing‐Ying; Cao, Ran‐Juan; Xing, Zhenkai; Kazim, Alia Rizvi Syeda; Yu, Huali; Zheng, Qing‐Chuan; Zhu, Xinen

doi:10.1111/jcmm.13547

Cited by 11 publications

(7 citation statements)

References 17 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among anti-FGF antibodies developed for therapeutic applications, FGF2 is the most commonly chosen target for selection of antibodies or antibody fragments [ 20 , 21 , 22 ], but there are also few reports on anti-FGF1 [ 24 , 38 ], anti-FGF8b [ 23 ], and anti-FGF23 [ 25 ]. Regarding antibodies binding FGF1, there is a scFv1C9 developed by the group of Xiao-Juan Zhu [ 24 , 38 , 39 ]. This small antibody is based on hybridoma derived from mouse immunized with FGF1 and inhibits growth of breast and glioma tumors in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 99%

Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity

Chudzian

Szlachcic

Zakrzewska

et al. 2018

IJMS

View full text Add to dashboard Cite

Fibroblast growth factor 1 (FGF1) and its receptors (FGFRs) regulate crucial biological processes such as cell proliferation and differentiation. Aberrant activation of FGFRs by their ligands can promote tumor growth and angiogenesis in many tumor types, including lung or breast cancer. The development of FGF1-targeting molecules with potential implications for the therapy of FGF1-driven tumors is recently being considered a promising approach in the treatment of cancer. In this study we have used phage display selection to find scFv antibody fragments selectively binding FGF1 and preventing it from binding to its receptor. Three identified scFv clones were expressed and characterized with regard to their binding to FGF1 and ability to interfere with FGF1-induced signaling cascades activation. In the next step the scFvs were cloned to scFv-Fc format, as dimeric Fc fusions prove beneficial in prospective therapeutic application. As expected, scFvs-Fc exhibited significantly increased affinity towards FGF1. We observed strong antiproliferative activity of the scFvs and scFvs-Fc in the in vitro cell models. Presented antibody fragments serve as novel FGF1 inhibitors and can be further utilized as powerful tools to use in the studies on the selective cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity

Chudzian

Szlachcic

Zakrzewska

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…It can be well produced by using prokaryotic expression in Escherichia coli. Applications of scFv against fibroblast growth factor receptor (FGFR) and fibroblast growth factor 1 (FGF-1) have shown a great anti-tumor effect both in vitro and in vivo (112)(113)(114). Recently, scFvs have also been applied in HPV-induced neoplasms by targeting oncoproteins, including HPV E5, E6, and E7.…”

Section: Intracellular Single-chain Antibodies (Scfvs) For the Therapeutics Of Hpv-induced Cancersmentioning

confidence: 99%

Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers

Dong

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Infection with human papillomavirus (HPV) is one of the main causes of malignant neoplasms, especially cervical, anogenital, and oropharyngeal cancers. Although we have developed preventive vaccines that can protect from HPV infection, there are still many new cases of HPV-related cancers worldwide. Early diagnosis and therapy are therefore important for the treatment of these diseases. As HPVs are the major contributors to these cancers, it is reasonable to develop reagents, kits, or devices to detect and eliminate HPVs for early diagnosis and therapeutics. Immunological methods are precise strategies that are promising for the accurate detection and blockade of HPVs. During the last decades, the mechanism of how HPVs induce neoplasms has been extensively elucidated, and several oncogenic HPV early proteins, including E5, E6, and E7, have been shown to be positively related to the oncogenesis and malignancy of HPV-induced cancers. These oncoproteins are promising biomarkers for diagnosis and as targets for the therapeutics of HPV-related cancers. Importantly, many specific monoclonal antibodies (mAbs), or newly designed antibody mimics, as well as new immunological kits, devices, and reagents have been developed for both the immunodiagnosis and immunotherapeutics of HPV-induced cancers. In the current review, we summarize the research progress in the immunodiagnosis and immunotherapeutics based on HPV for HPV-induced cancers. In particular, we depict the most promising serological methods for the detection of HPV infection and several therapeutical immunotherapeutics based on HPV, using immunological tools, including native mAbs, radio-labelled mAbs, affitoxins (affibody-linked toxins), intracellular single-chain antibodies (scFvs), nanobodies, therapeutical vaccines, and T-cell-based therapies. Our review aims to provide new clues for researchers to develop novel strategies and methods for the diagnosis and treatment of HPV-induced tumors.

show abstract

“…The most common histologic subtypes of glioma are astrocytoma and oligodendroglioma [2]. Despite multimodal therapeutic strategy, such as chemotherapy, radiotherapy and other adjuvant therapy have been combined to combat glioma over the last decade, the prognosis of glioma patients remains unoptimistic [3,4]. Lack of efficient and novel molecular target in clinical treatment is a vital reason for the unsatisfactory outcome [5].…”

Section: Introductionmentioning

confidence: 99%

EIF3J-AS1 promotes glioma cell growth via up-regulating ANXA11 through sponging miR-1343-3p

Jing

Wang²,

Zhao

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: Glioma is one prevalent malignant tumor originates from the central nervous system. Dysregulation of long non-coding RNAs (lncRNAs) has been found to be a molecular signature behind the pathology of a variety of cancers, including glioma. EIF3J antisense RNA 1 (EIF3J-AS1) is a novel lncRNA, whose performance in carcinogenesis has been unfolded. Nevertheless, the role of EIF3J-AS1 has never been investigated in glioma. Methods: qRT-PCR analysis was adopted to evaluate the relative levels of RNAs. In vitro functional assays, including colony formation, EdU, TUNEL and caspase-3/8/9 activity assays were conducted to study the impacts of EIF3J-AS1 on glioma. Dual-luciferase activity assays, RNA pull down assay and RIP assay were performed to elucidate molecular interplay among genes. Results: EIF3J-AS1 was overexpressed in glioma cell lines. Knockdown of EIF3J-AS1 hampered glioma malignant phenotypes. MiR-1343-3p could bind to EIF3J-AS1. Moreover, miR-1343-3p targeted Annexin A11 (ANXA11) in its 3′UTR region. Mechanistically, EIF3J-AS1 relieved ANXA11 from miR-1343-3p silencing in the EIF3J-AS1/miR-1343-3p/ ANXA11 RNA induced silencing complex (RISC), thus eliciting promoting effects on glioma progression. MiR-1343-3p inhibitor and ANXA11 overexpression offset the inhibitory impacts of EIF3J-AS1 silencing on glioma development. Conclusion: EIF3J-AS1/miR-1343-3p/ANXA11 axis significantly affected biological behaviors in glioma, suggesting new therapeutic target for glioma treatment.

show abstract

Humanization of fibroblast growth factor 1 single‐chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells

Cited by 11 publications

References 17 publications

Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity

Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity

Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers

EIF3J-AS1 promotes glioma cell growth via up-regulating ANXA11 through sponging miR-1343-3p

Contact Info

Product

Resources

About